Adaptive Biotechnologies Corp
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
7. Leases
We have operating lease agreements for laboratory, office and warehouse facilities in Seattle, Washington, South San Francisco, California and Bothell, Washington. As of March 31, 2026, we were not party to any finance leases.
The following table reconciles our undiscounted operating lease cash flows to our operating lease liabilities, less current portion balance on the unaudited condensed consolidated balance sheet as of March 31, 2026 (in thousands):
| 2026 (excluding the three months ended March 31, 2026) | $8,822 |
| 2027 | 12,462 |
| 2028 | 12,818 |
| 2029 | 12,860 |
| 2030 | 12,988 |
| Thereafter | 31,344 |
| Total undiscounted lease payments | 91,294 |
| Less: Imputed interest | (13,666) |
| Total operating lease liabilities | 77,628 |
| Less: Current portion | (8,513) |
| Operating lease liabilities, less current portion | $69,115 |
During the three months ended March 31, 2026 and 2025, cash paid for amounts included in the measurement of lease liabilities was$3.5 million and $3.0 million, respectively.
We have $2.1 million in letters of credit with one of our financial institutions in connection with certain of our leases.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.